



ENKORTEN®

ENKORTEN®






DRUG STRUCTURE

ENKORTEN® is made from two endogenous neuropeptides and has excellent safety profile.

ENKORTEN® is a drug belonging to the group of Other immunostimulants, it has immunomodulatory activity.



IMMUNOMODULATION IN COVID-19

ENKORTEN® is approved for use in the treatment of auto-immune disease multiple sclerosis, its relapse-remitting form as the most common one. ENKORTEN® is found to have efficacy and safety in treatment of moderate and severe COVID-19 patients. The main target of ENKORTEN® is cytokine storm. Registration of additional indication of COVID-19 is ongoing.

Clinical studies showed promising results and a possible use of ENKORTEN® in treatment of some other auto-immune diseases such as asthma as well as ulcerative colitis and Crohn's disease.



LOREM IPSUM

ENKORTEN® is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960's with the release of Letraset sheets containing

Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.





Legend:

- ENKORTEN®
- Standard therapy
- ENKORTEN® - censored
- Standard therapy - censored

EFFICACY


An open-label, prospective, randomized, comparative clinical trial to evaluate the efficacy and safety of ENKORTEN® as an immunomodulatory therapy, within the usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection.

The primary efficacy outcome was time to onset of improvement in the patient's clinical condition and it was found that the ENKORTEN® group had a significantly shorter time to 7 and 14-day clinical improvement compared to the standard therapy group.

SAFETY

An open-label, prospective, randomized, comparative clinical trial to evaluate the efficacy and safety of ENKORTEN® as an immunomodulatory therapy, within the usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection.

An open-label, prospective, randomized, comparative clinical trial to evaluate the efficacy and safety of ENKORTEN® as an immunomodulatory therapy, within the usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection.



Aktivni patenti čiji je vlasnik BOSNALIJEK su prikazani u tabeli:

Država	Njemačka	Turska	US	Ruska Federacija
Broj prijave patenta	Ep01988010	2012/11793	Us10492908	Ru2014114992
Broj objave patenta	Ep1435999	2012 11793	Us7544653	Ru2297238
Datum prijave	29.11.2001.	29.11.2001.	29.11.2001.	29.11.2001.
Datum isteka	29.11.2021.	29.11.2021.	29.11.2021.	29.11.2021.
Naziv patenta/ Prijave patenta	KOMBINATION VON ZWEI BIOAKTIVEN REGIONEN DES PRO- OPIOMELANOCORTINS	UĞUR GÜRŞAD YALÇINER (YALÇINER PATENT VE DAN. LTD. ŞTİ.)	ADDITIVE CYTOPROTECTIVE EFFECTS OF TWO BIOACTIVE REGIONS OF PRO- OPIOMELANOCORTIN HORMONE	АДДИТИВНЫЕ ЦИТОПРОТЕКТОРНЫЕ ЭФФЕКТЫ ДВУХ БИОАКТИВНЫХ ОБЛАСТЕЙ ГОРМОНА ПРО- ОПИОМЕЛАНКОРТИНА



ENKORTEN® PATENTED DRUG

Active substances are produced in USA, lyophilized and packed in primary packaging in Germany, final production is performed in Bosnalijek.

According to the Agreement of transfer of rights signed with the innovator of drug metenkefalin and tridecactide, brand name Enkorten, Bosnalijek has acquired patents Germany (no. EP1435999), Turkey (No.2012 11793), United State of America (No. US7544653) and Russian Federation (No. RU2297238) and trademark Enkorten.

Aktivni patenti čiji je vlasnik Bosnalijek su prikazani u tabeli:

KEY INVESTMENT CONSIDERATION

ENKORTEN® is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960's with the release of Letraset sheets containing

Lorem Ipsum passages, and more recently with desktop publishing software



- Well established molecules benefitting from historical legacy
- More than 50 clinical trials conducted
- Very well-known molecule in the medical community
- Proven efficacy and well-known safety profile
- Naturally occurring molecule
- Awarded products
 - CONSUMER HEALTH AWARD 2017: the First-Choice Medicine and best-seller in category of sore throat medication in Russia;
 - GREEN CROSS AWARD 2018, Product of the Year in the category of sore throat remedies
- Large spectrum of pharmacological actions with the focus on:
 - inflammatory condition of the oral cavity and pharynx,
 - painful, irritated and inflamed throat and pharynx,
 - pre- and post-operative usage in cases of tonsillectomy, larynx surgery, injury or abscess, and following tooth extraction.
- Complementary forms to fit every patient
- Increasing market of OTC drugs for sore throat, cold and flu
- Opportunity to create new strengths and new formulation
- Opportunity to increase prices
- Potential for re-initiation of promotion after a period without marketing efforts / investments
- Unique formulation on the market - easy differentiation and market penetration



TRUSTED
MOLECULE



WIDE
THERAPEUTICAL
USE



POTENTIAL FOR
GROWTH

EFFECTS	Lysobact® Lysobact P Spray®	Lysobact Spray® Lysobact DUO®	Lysobact Complete Spray®	Other oral antiseptic
ANTIMICROBIC	✓	✓ ✓	✓ ✓	✓
ANALGETIC (indirect)	✓	✓	✓	— ✓
ANAESTHETIC	—	—	✓	— ✓
ANTI-INFLAMMATORY	✓	✓	✓	— ✓
PRO-REGENERATIVE	✓	✓	✓	—
MUCOPROTECTIVE	✓	✓	✓	—
IMMUNOMODULATORY	✓	✓	✓	—
ANTI-ALLERGIC	✓	✓	✓	—
ANTI-PLAQUE	✓	✓	✓	—
NOTE	Contains lysozyme and vitamine B6 for extra protection mucosal	Contains lysozyme and cetylpyridinium for synergistic antimicrobial effect	Contains lysozyme, cetylpyridinium and lidocaine for synergistic antimicrobial and anaesthetic effect	Without lysozyme



MARKET

ENKORTEN® is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960's with the release of Letraset sheets containing

Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.



REVIEW OF THE COMPETITION



There are other immunomodulators tested or used in COVID-19.

Enkorten has huge advantage of being effective and in the same time has extremely safe profile with very AEs registered during the use of ENKORTEN® are mild and usually linked to immediate use of the drug. All AEs are short-lasting and reversible.

Other immunomodulators have less acceptable safety profile

The most common side effects of tocilizumab are infections (staphylococcal cellulitis, acute pyelonephritis and sepsis, angioedema and urticaria, chickenpox, and bacterial arthritis). Also, one death of the patient was recorded because there was bleeding and perforation in the upper digestive organs after administration of tocilizumab in combination with corticosteroids.





